Welcome to our dedicated page for Cencora news (Ticker: COR), a resource for investors and traders seeking the latest updates and insights on Cencora stock.
Cencora, Inc. reports news around its role as a global pharmaceutical solutions organization that distributes branded, generic and specialty pharmaceuticals to pharmacies, hospital networks and healthcare providers. Company updates also cover commercialization services for pharmaceutical and medical-device manufacturers, specialty drug logistics through World Courier, animal health distribution through MWI Animal Health and international wholesale activity following the Alliance Healthcare acquisition.
Recurring developments include fiscal operating results, gross profit drivers, LIFO effects, GLP-1 product mix and performance in U.S. Healthcare Solutions. News also covers completed acquisitions such as OneOncology and Retina Consultants of America, senior note financing, shareholder and governance matters, and executive leadership transitions.
Cencora (NYSE: COR) will release its Third Quarter Fiscal 2024 results on Wednesday, July 31, 2024, before the NYSE opens. A conference call to discuss these results is scheduled for 8:30 a.m. ET the same day, featuring top executives Steven H. Collis, James F. Cleary, and Robert P. Mauch. The call will be webcast live on the company's investor relations website and accessible via telephone. Replays will be available both online and by phone, with details provided for access. Cencora is a leading global pharmaceutical solutions organization, ranked #10 on the Fortune 500, with over $250 billion in annual revenue and a workforce of over 46,000 employees globally.
Kehoe Law Firm is investigating potential claims for individuals affected by a data breach at Cencora (NYSE: COR). On February 21, 2024, Cencora discovered data exfiltration from its systems, including personal and medical information. By May 24, 2024, TechCrunch reported that Cencora had notified around 500,000 individuals, with the total number expected to be much higher, as Cencora serves over 18 million patients. Compromised data includes patient names, addresses, dates of birth, health diagnoses, and medications.
Cencora (NYSE: COR) has announced a significant share repurchase agreement with Walgreens Boots Alliance Holdings, totaling approximately $400 million. This transaction is part of a broader strategy, with Cencora completing around $550 million in share repurchases in May 2024 alone. Additionally, Cencora has raised its fiscal year 2024 adjusted diluted earnings per share (EPS) guidance to a range of $13.35 to $13.55, up from the previous $13.30 to $13.50. The improved EPS forecast is attributed to a reduced share count, although it is partially offset by increased net interest expenses due to lower investment balances following the repurchases. Cencora, a global pharmaceutical solutions leader, is recognized on the Fortune 500 and Global Fortune 500 lists, with annual revenues exceeding $250 billion.
Walgreens Boots Alliance (WBA) has sold approximately $400 million worth of Cencora (COR) shares through a stock repurchase agreement, decreasing its ownership from 13% to 12%.
The proceeds will be used mainly for debt reduction and general corporate purposes, supporting WBA's strategy to enhance its health services rooted in retail pharmacy.
The sale does not affect the ongoing collaboration or long-term strategic partnership between the companies. Ornella Barra, COO International of WBA, will continue to serve on Cencora's Board of Directors.
Cencora, Inc. (NYSE: COR) reported a revenue of $68.4 billion for the second quarter, marking a 7.8% increase year-over-year. The GAAP diluted EPS stood at $2.09, with adjusted diluted EPS at $3.80. The company raised its adjusted diluted EPS guidance range to $13.30 to $13.50 for fiscal 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.